Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

American Heart Journal

Topics

Physics

Quantum Mechanics

Medicine

Immunology

Internal Medicine

Show all topics

DOI

10.1016/j.ahj.2014.07.028

License

CC-BY-NC-ND

Other Formats

PDF